EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Candidemia in immunocompromised patients


Clinical Infectious Diseases 14 Suppl 1: S120-S125
Candidemia in immunocompromised patients
This study reviews data on patients with fungemia and confirms the high prevalence (50%) of infections caused by non-albicans species of Candida. Fungemia due to C. albicans or Torulopsis glabrata occurred significantly more often in patients with a solid tumor, while fungemia due to Candida tropicalis or Candida krusei was significantly more common in patients with hematologic malignancy (P = .001). For 31% of patients, only a single blood culture was positive for yeasts, and the prognosis for these patients was not significantly different than that for patients with three or more positive blood cultures (P = 1), including those who had C. albicans fungemia. The overall mortality rate was 41.8%, which is much lower than that previously reported in studies of patients with cancer. No significant difference was observed between patients treated with amphotericin B and those treated with fluconazole in this retrospective analysis. Although no significant difference was observed in the mortality rate among patients who had fungemia with or without neutropenia, the incidence of disseminated candidiasis was significantly higher among neutropenic patients (P = .03).


Accession: 002042517

PMID: 1562683

DOI: 10.1093/clinids/14.supplement_1.s120



Related references

Investigation of the sequence of colonization and candidemia in non-immunocompromised patients. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33(0): 131, 1993

Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clinical Infectious Diseases 26(2): 461-467, 1998

Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. European Journal of Clinical Microbiology & Infectious Diseases 26(6): 377-384, 2007

Investigation of an outbreak of Candida parapsilosis candidemia in immunocompromised children. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 239, 1996

Candidemia in adult HIV positive patients A report of five cases without risk factors for candidemia. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Eleventh International Conference on AIDS, Vol Two One world: One hope : 94, 1996

Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 124(6): 2244-2255, 2003

Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infection Control and Hospital Epidemiology 23(9): 542-545, 2002

Prospective study for diagnosis of candidemia by PCR and blood cultures and variables associated with the development of candidemia in high risk patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 461, 2003

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. New England Journal of Medicine 331(20): 1325-1330, 1994

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. European Journal of Clinical Microbiology & Infectious Diseases 16(5): 337-345, 1997